Insmed INSM
NASDAQ INSM
$119.49 +3.39 (+2.92%)
At close: Nov 10, 2026 · 4:00 PM EST

Insmed (INSM) Current Deferred Revenue (2010 - 2011)

Updated

Insmed's Current Deferred Revenue came in at $421,000 for Q3 2011, up 115.9% from the prior quarter.

Analysis

Insmed (INSM) Current Deferred Revenue (2010 - 2011) Analysis & Trends

At the end of FY2010, Insmed's Current Deferred Revenue was $402,000.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,264.65 Bn 1,238.27 Bn 20.46 Bn
2 Johnson & Johnson 677.74 Bn 597.60 Bn 17.30 Bn
3 AbbVie 517.10 Bn 485.11 Bn 13.12 Bn
4 Merck 362.23 Bn 325.17 Bn 13.19 Bn
5 Novartis Ag 315.90 Bn 276.16 Bn 11.24 Bn
6 Astrazeneca 289.40 Bn 266.24 Bn 12.86 Bn
7 Amgen 249.90 Bn 201.56 Bn 7.58 Bn
8 Gilead Sciences 209.15 Bn 184.26 Bn 6.73 Bn
9 Pfizer 165.88 Bn 113.23 Bn 12.56 Bn
10 Insmed 25.82 Bn 20.86 Bn 446.21 Mn
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2011 421,000.00
Jun 30, 2011 195,000.00
Dec 31, 2010 402,000.00
API Access

Insmed Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=INSM&period=max&api_key=YOUR_API_KEY